

family. This family currently consists of NGF (nerve growth factor), BDNF (brain derived neurotrophic factor), NT-3 (neurotrophin-3), NT-4 (neurotrophin-4), and NT-6 (neurotrophin-6).

5 CNTF (ciliary neurotrophic factor) and LIF (leukemia inhibitory factor) are cytokine polypeptides that have neurotrophic activity. By virtue of their structural features and receptor components, these polypeptides are related to a family of hematopoietic
10 cytokines that includes IL-6 (interleukin-6), IL-11 (interleukin-11), G-CSF (granulocyte-colony stimulating factor), and oncostatin-M.

Recently, several naturally occurring neurotrophic factors have been identified based on
15 their trophic activity on various neurons. These novel polypeptides, referred to as "novel neurotrophic factors" or "NNT-1," are disclosed in U.S. Patent No. 5,741,772 (Chang), the disclosure of which is herein incorporated by reference in its entirety. NNT-1, a
20 cytokine of the IL-6 family, was found to be useful in promoting neuron regeneration and restoring neural functions. In addition to novel NNT-1 polypeptides, the Chang patent disclosed, among other things, related biologically active polypeptide fragments and
25 derivatives thereof (i.e. having neurotrophic activity), novel nucleic acid molecules encoding such polypeptides, vectors comprising these nucleic acid molecules, host cells comprising the vectors, antibodies to NNT-1, methods of preparing NNT-1
30 polypeptides, therapeutic compositions containing NNT-1 polypeptides, assays to screen for inhibitors of NNT-1, transgenic mammals in which the gene(s) encoding the human equivalent of NNT-1 has been disrupted ("knocked out") and methods of treating diseases and disorders of
35 the nervous system using NNT-1.

5 In addition, the use of NNT-1 to treat
certain IgG and IgM-related immunological diseases was
identified and discussed in pending PCT WO 98/33922,
the disclosure of which is also incorporated herein by
reference in its entirety. In that application,
evidence was presented that NNT-1 compounds may have a
biological activity of modulating the immune system,
and in particular, causing an increase in B-cell and T-
cell production. Thus, in addition to neurotrophic
10 properties, NNT-1 demonstrates B-cell stimulating
activity, which consists of the induction of lymphoid
hyperplasia and elevation of serum IgG and IgM. See
also Senaldi, et al., *Novel Neurotrophin-1/B Cell-
Stimulating Factor-3: A Cytokine Of The IL-6 Family*,
15 *Proc. Natl. Acad. Sci., USA*, Vol. 96, pp. 11458-11463
(Sept. 1999).

Of particular interest in the area of
immunological disorders are allergy and asthma.
Allergy and asthma are debilitating diseases that
20 afflict nearly 20 percent of the population of
industrialized countries. For reasons still not well
understood, allergic individuals produce increased
amounts of IgE with binding specificity for ordinarily
innocuous antigens, such as pollen, animal fur,
25 certain foods, etc., collectively termed "allergens."
These IgE molecules circulate in the blood and bind to
IgE-specific receptors on the surface of basophils and
mast cells.

In an allergic reaction, the inhaled or
30 ingested allergens bind to IgE on these mast cells or
basophils, crosslink the IgE molecules, and aggregate
the underlying receptors, thus triggering the cells to
release histamine and the other pharmacological
mediators of the symptomatic allergic response.
35 Antigen-specific IgE has thus been shown to play a key
role in the physiopathology of allergic disorders.

See, Arm, *Advances In Immunology*, 51:323-383 (1992);
Rosenwasser, *Journal of Allergy and Clinical
Immunology*, 105:S586-S591 (2000); Change, *Nature
Biotechnology*, 18:157-162 (2000).

5 It is well-established that at least one
common feature that distinguishes allergic individuals
from others is their abnormally high levels of IgE.
There is currently no reliable cure for allergy and no
approved treatment that corrects the overproduction of
10 IgE. Current drugs for allergic diseases, such as
antihistamines, corticosteroids, and bronchodilators
(β -adrenergic receptor antagonists), treat allergic
symptoms and concomitant inflammatory reactions.
Desensitization immunization with antigens (allergens),
15 which is used mainly in the United States for allergic
rhinitis, is not effective for about half of the
treated patients. Therefore, a treatment that targets
the allergic process, prevents it from occurring, and
has fewer side effects than current drugs is desirable.

20 Accordingly, it is an object of the present
invention to provide a method and composition for
treating and/or preventing IgE-related diseases such as
allergy and asthma. It is a further object of the
invention to provide a novel use for NNT-1 inhibitors
25 in the treatment of certain IgE-related immunological
diseases and disorders.

 It is still a further object of the invention
to provide a method of inhibiting antigen-specific IgE
production by inhibiting the activity, production
30 and/or expression of NNT-1.

 It is still another object of the present
invention to provide a method of treating or preventing
IgE-related disease using NNT-1 inhibitors.

 These and other objects will be apparent to
35 one of ordinary skill in the art from the present
disclosure.

SUMMARY OF THE INVENTION

In one embodiment, the present invention
5 relates to a method of treating IgE-related disease
comprising administering to a patient a therapeutically
effective amount of an NNT-1 inhibitor. In another
embodiment, the present invention relates to a method
of treating IgE-related disease comprising
10 administering to a patient an NNT-1 inhibitor which is
capable of inhibiting binding to at least one
polypeptide selected from the group consisting of:

- a) a polypeptide comprising the amino acid
sequences of SEQ ID NOS: 2, 4 or 5;
- 15 b) a polypeptide encoded by a nucleic acid
sequence of SEQ ID NOS: 1 or 3;
- c) a biologically active fragment of the
polypeptides of a) or b); or
- d) a naturally occurring variant of a), b) or
20 c).

In another embodiment, the present invention
provides a novel method of modulating IgE levels in a
patient comprising administering to said patient a
therapeutically effective amount of an NNT-1 inhibitor.

25 In still another embodiment, the present
invention provides a novel method for treating allergic
disease comprising administering to a patient a
therapeutically effective amount of an NNT-1 inhibitor.

In an additional embodiment, the present
30 invention provides a method of using an NNT-1 inhibitor
to modulate the levels of IgE in a patient.

In yet another embodiment, the present
invention relates to a method of diagnosing an IgE-
related disease or susceptibility to an IgE- related
35 disease comprising:

a) determining the presence or amount of expression of at least one polypeptide selected from the group consisting of:

- 5 i) a polypeptide comprising the amino acid sequences of SEQ ID NOS: 2,4, or 5;
- ii) a polypeptide encoded by a nucleic acid sequence of SEQ ID NOS: 1 or 3;
- iii) a fragment of the polypeptide of i) or ii) above;
- 10 iv) a naturally occurring variant of i), ii) or iii); and

b) diagnosing an IgE-related disease or susceptibility to an IgE-related disease based on the presence or amount of expression of the polypeptide.
15 using NNT-1 inhibitors

In still another embodiment, the present invention relates to a method of preventing an IgE-related disease comprising administering to a patient a therapeutically effective amount of an NNT-1 inhibitor.

20 In still a further embodiment, the present invention relates to a pharmaceutical composition for use in treating IgE-related disease comprising a therapeutically effective amount of an NNT-1 inhibitor.

25 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the nucleic acid sequence of the cDNA encoding human NNT-1 (SEQ ID NO:1).

30 Figure 2 depicts the nucleic acid sequence of the human genomic DNA for NNT-1 (SEQ ID NO:3).

Figure 3 depicts the amino acid sequence for human NNT-1 (SEQ ID NO:1) as translated from the cDNA (SEQ ID
35 NO:2). The first 27 amino acids may represent a signal peptide sequence, such that the mature form of NNT-1

Sub A1

starts at the leucine indicated as number 1. The * indicates the stop codon.

Figure 4 depicts the nucleic acid sequence of the cDNA encoding murine NNT-1 (SEQ ID NO:4).

Figure 5 depicts the amino acid sequence for murine NNT-1 (SEQ ID NO:5) as translated from the cDNA (SEQ ID NO:4). The first 27 amino acids may represent a signal peptide sequence, such that the mature form of murine NNT-1 starts at the leucine, indicated as number 1. The * indicates the stop codon.

Figure 6 depicts serum levels of anti-KLH IgE in Balb/c mice treated for seven days with NNT-1 or NNT-1 solvent as a control and in NNT-1 transgenic mice (Tg+) and in littermate controls (Tg-).

Figure 7 depict serum levels of anti-KLH IgE in NNT-1 transgenic mice (Tg+) and in littermate controls (Tg-) bled on days 7, 14 and 21.

DETAILED DESCRIPTION OF THE INVENTION

It has, surprisingly, been found that NNT-1, a novel neurotrophic factor, is also able to induce elevation of total IgE in serum and to stimulate antigen-specific IgE production. The finding that NNT-1 is able to modulate levels of serum IgE strongly suggests that NNT-1 may be involved in the pathogenesis of IgE-related disease, such as allergy and asthma. Pharmacologically attacking or inhibiting NNT-1 may represent a new therapeutic approach to the treatment and/or prevention of certain IgE-related diseases and disorders.

Accordingly, the present invention provides a method for treating IgE-related disease by administering a therapeutically effective amount of an NNT-1 inhibitor, such as an anti-NNT-1 antagonist
5 antibody. Specifically included in the scope of this invention is the use of agents that inhibit or reduce the production, expression or activity of NNT-1, including but not limited to antibodies, peptides, fusion peptides, oligonucleotides, small molecules,
10 soluble receptor proteins, and other agents that function to inhibit or decrease the activity, production or expression of NNT-1, and/or related biologically active polypeptide fragments, derivatives and variants thereof. Also contemplated are agents
15 which similarly effect the NNT-1 receptor (i.e., agents which prevent signal transduction in the NNT-1 receptor) as well as agents that modulate the expression of NNT-1 or its receptor.

The section headings used herein are for
20 organizational purposes only and are not to be construed as limiting the subject matter described. All references cited in this section are expressly incorporated by reference herein.

25 I. NNT-1 Proteins/Polypeptides, Fragments, Derivatives and Variants Thereof

The term "NNT-1 protein" or "NNT-1 polypeptide" as used herein refers to any protein or
30 polypeptide disclosed or described in, or having the properties described in U.S. Patent No. 5,471,772. By way of illustration, NNT-1 protein or NNT-1 polypeptide refers to:

- 35 (1) an amino acid sequence encoded by NNT-1 nucleic acid molecules as defined in any of the following items:

(a) the nucleic acid molecule of SEQ ID
NO: 1;

(b) the nucleic acid molecule of SEQ ID
NO: 3;

5 (c) a nucleic acid molecule encoding the
polypeptide of SEQ ID NO: 2, or a biologically active
fragment thereof;

(d) a nucleic acid molecule that encodes
a polypeptide that is at least 70 percent identical to
10 the polypeptide of SEQ ID NO: 2;

(e) a nucleic acid molecule that
hybridizes under stringent conditions to any of (a)-(d)
above;

(f) a nucleic acid molecule that is the
15 complement of any of (a)-(e) above; and

(a') the nucleic acid molecule of SEQ
ID NO:4;

(b') a nucleic acid molecule encoding
the polypeptide of SEQ ID NO:5 or a biologically active
20 fragment thereof;

(c') a nucleic acid molecule that
encodes a polypeptide that is at least 70 percent
identical to the polypeptide of SEQ ID NO:5;

(d') a nucleic acid molecule that
25 hybridizes under stringent conditions to any of (a')-
(c') above; and

(e') a nucleic acid molecule that is
the complement of any of (a')-(d') above;

(2) related biologically active polypeptides
30 and fragments and derivatives thereof;

(3) naturally occurring allelic variants of
the NNT-1 gene which result in one or more amino acid
substitutions, deletions, and/or insertions as compared
to the NNT-1 polypeptide of SEQ ID NO:2 or SEQ ID NO:
35 5, and/or

(4) chemically modified derivatives as well as nucleic acid and/or amino acid sequence variants, splice variants, derivatives, and orthologs.

The NNT-1 polypeptides may be naturally occurring full length polypeptides, or truncated polypeptides or peptides (*i.e.*, "fragments"). The polypeptides may be in mature form or they may be attached to a native or heterogeneous signal peptide. For example, human and murine NNT-1 have signal peptides of amino acids -27 to -1 of SEQ ID NOS: 2 and 5, respectively.

The polypeptides or fragments may be chemically modified, *i.e.*, glycosylated, phosphorylated, and/or linked to a polymer, as described below, and they may have an amino terminal methionine, depending on how they are prepared. In addition, the polypeptides or fragments may be variants of the naturally occurring NNT-1 polypeptide (*i.e.*, may contain one or more amino acid deletions, insertions, and/or substitutions as compared with naturally occurring NNT-1).

As used herein, the term "fragment" refers to a peptide or polypeptide that is less than the full length amino acid sequence of naturally occurring NNT-1 protein. It may comprise a truncation at the amino terminus (with or without a leader sequence) and/or a truncation at the carboxy terminus of the polypeptide as set forth in SEQ ID NO: 2, allelic variants, orthologs, splice variants and/or variants having one or more amino acid additions or substitutions or internal deletions (where the resulting polypeptide is at least 6 amino acids or more in length) as compared to the amino acid sequence set forth in SEQ ID NO: 2. NNT-1 fragments may result from alternative RNA splicing or from *in vivo* protease activity and additionally include soluble forms such as those

lacking a transmembrane or membrane binding domain. Further, such fragments may be chemically modified and/or may be prepared with or without an amino terminal methionine.

5 As used herein, the term "biologically active fragment" refers to a fragment that has, qualitatively, a substantially similar type of biological activity as full length, mature NNT-1 polypeptide described above. Preferably, the activity of the fragment is $\geq 50\%$, more
10 preferably $\geq 65\%$, most preferably $\geq 80\%$, of the activity of the full-length polypeptide, as measured by a standard activity assay. Some exemplary fragments include the polypeptides wherein from 1 to 20 amino acids are removed from either the C-terminus, the N-
15 terminus, or both termini, of the NNT-1 polypeptide. Examples of biological activity include the ability to act as a growth factor for neurons (e.g., motor neurons and/or sympathetic neurons) or of modulating the immune system (e.g., causing an increase in B-cell and/or T-
20 cell production).

 Fragments and/or derivatives of NNT-1 that are not themselves active in activity assays may be useful as modulators of the NNT-1 receptors *in vitro* or *in vivo*, or to prepare antibodies to NNT-1
25 polypeptides.

 As used herein, the term "allelic variants" refers to one of several possible naturally occurring alternate forms of the gene occupying a given locus on a chromosome or a population of organisms.

30 As used herein, the term "derivative" refers to an NNT-1 polypeptide, protein, fragment, allelic variant, ortholog, splice variant or variant thereof that; 1) has been chemically modified, as for example, by addition of one or more polyethylene glycol
35 molecules, sugars, phosphates, or other such molecules not naturally attached to wild-type NNT-1 polypeptide,

Percent sequence identity can be determined by standard methods that are commonly used to compare the similarity in position of the amino acids of two polypeptides. By way of example, using a computer program such as BLAST or FASTA, the two polypeptides for which the percent sequence identity is to be determined are aligned for optimal matching of their respective amino acids (the "matched span," which can include the full length of one or both sequences, or a predetermined portion of one or both sequences). Each computer program provides a "default" opening penalty and a "default" gap penalty, and a scoring matrix such as PAM 250. A standard scoring matrix (see Dayhoff et al., in: *Atlas of Protein Sequence and Structure*, vol. 5, supp.3 [1978]) can be used in conjunction with the computer program. The percent identity can then be calculated using an algorithm contained in a program such as FASTA as:

$$\frac{\text{Total number of identical matches}}{[\text{length of the longer sequence within the matched span}] + [\text{number of gaps introduced into the longer sequence in order to align the two sequences}]} \times 100$$

Polypeptides that are at least 70 percent identical will typically have one or more amino acid substitutions, deletions, and/or insertions as compared with wild type NNT-1. Usually, the substitutions will be conservative so as to have little or no effect on the overall net charge, polarity, or hydrophobicity of the protein but optionally may increase the activity of NNT-1. Conservative substitutions are set forth in Table I below.

Table I

Conservative amino acid substitutions

Basic:	arginine
	lysine
	histidine
Acidic:	glutamic acid
	aspartic acid
Polar:	glutamine
	asparagine
Hydrophobic:	leucine
	isoleucine
	valine
Aromatic:	phenylalanine
	tryptophan
	tyrosine
Small:	glycine
	alanine
	serine
	threonine
	methionine

5 Also contemplated are species homologs or
orthologs of NNT-1; for example, NNT-1 orthologs from a
mammalian species such as dog, cat, mouse, rat, monkey,
horse, pig, goat, rabbit, sheep and the like is
contemplated in addition to human. The sequences of
10 murine cDNA and protein are provided as SEQ ID NOS: 4
and 5.

As indicated previously, the NNT-1
polypeptide referred to herein also includes chemically
modified derivatives, such as glycosylation variants
15 wherein the number and/or type of glycosylation sites
has been altered compared to the amino acid sequence
set forth in SEQ ID NO: 2. For example, an NNT-1
variant may contain a greater or a lesser number of N-

linked glycosylation sites than the amino acid sequence set forth in SEQ ID NO: 2. An N-linked glycosylation site is characterized by the sequence: Asn-X-Ser or Ans-X-Thr, wherein the amino acid residue designated as X may be any amino acid residue other than proline. Alternatively, substitutions which eliminate this sequence will remove an existing N-linked carbohydrate chain. Also contemplated is a rearrangement of N-linked glycosylation sites (typically those naturally occurring) are eliminated and one or more new N-linked sites are created. Additional variants include cysteine variants, wherein one or more cysteine residues are deleted from or substituted for another amino acid (e.g., serine) as compared to the amino acid sequence set forth in SEQ ID NO: 2.

II. Nucleic Acids

As used herein, the term "NNT-1" when used to describe a nucleic acid molecule refers to a nucleic acid molecule or fragment thereof, as set forth above.

The term "nucleic acid sequence" or "nucleic acid molecule" refers to a DNA or RNA sequence. The term encompasses molecules formed from any of the known base analogs of DNA and RNA such as, but not limited to 4-acetylcytosine, 8-hydroxy-N6-methyladenosine, aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxymethyl) uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-carboxy-methylaminomethyluracil, dihydrouracil, inosine, N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyamino-methyl-2-thiouracil, beta-D-

mannosylqueosine, 5' -methoxycarbonyl-methyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, oxybutoxosine, pseudouracil, queosine, 2-
5 thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine.

The term "naturally occurring" or "native"
10 when used in connection with biological materials such as nucleic acid molecules, polypeptides, and the like, refers to materials which are found in nature and are not manipulated by man. Similarly, "non-naturally occurring" or "non-native" as used herein refers to a
15 material that is not found in nature or that has been structurally modified or synthesized by man.

The term "stringent conditions" refers to hybridization and washing under conditions that permit only binding of a nucleic acid molecule such as an
20 oligonucleotide or cDNA molecule probe to highly homologous sequences. One stringent wash solution is 0.015 M NaCl, 0.005 M NaCitrate, and 0.1 percent SDS used at a temperature of 55°C-65°C. Another stringent wash solution is 0.2 X SSC and 0.1 percent SDS used at
25 a temperature of between 50°C-65°C. Where oligonucleotide probes are used to screen cDNA or genomic libraries, the following stringent washing conditions may be used. One protocol uses 6 X SSC with 0.05 percent sodium pyrophosphate at a temperature of
30 35°C-62°C, depending on the length of the oligonucleotide probe. For example, 14 base pair probes are washed at 35-40°C, 17 base pair probes are washed at 45-50°C, 20 base pair probes are washed at 52-57°C, and 23 base pair probes are washed at 57-63°C.
35 The temperature can be increased 2-3°C where the background non-specific binding appears high. A second

protocol utilizes tetramethylammonium chloride (TMAC) for washing oligonucleotide probes. One stringent washing solution is 3 M TMAC, 50 mM Tris-HCl, pH 8.0, and 0.2 percent SDS. The washing temperature using this solution is a function of the length of the probe. For example, a 17 base pair probe is washed at about 45-50°C.

NNT-1 nucleic acid molecules, fragments, and/or derivatives that do not themselves encode polypeptides that are active in activity assays may be useful as hybridization probes in diagnostic assays to test, either qualitatively or quantitatively, for the presence of NNT-1 DNA or RNA in mammalian tissue or bodily fluid samples.

NNT-1 nucleic acid molecules encoding NNT-1 polypeptides attached to native or heterogeneous signal peptides as described herein above are also contemplated.

III. NNT-1 Inhibitors

As used herein, the term "NNT-1 inhibitor" refers to an agent which is capable of inhibiting the production, activity or expression of NNT-1 (as defined above) or its receptor. Specifically contemplated are agents that bind, antagonize, inhibit or modulate the NNT-1 polypeptide and/or the NNT-1 receptor. Also contemplated are expression modulators which effect either the NNT-1 polypeptide or its receptor, including but not limited to ribozymes and small molecules.

One sub-class of such inhibitors may be referred to as "selective binding agents" or "SBAs." As used herein, "selective binding agent" refers to a molecule which is capable of specifically binding to an NNT-1 polypeptide, fragment, derivative or variant thereof or the NNT-1 receptor. Suitable selective binding agents include, but are not limited to, antibodies and

derivatives thereof, polypeptides, fusion polypeptides (i.e., part peptide, part antibody), soluble receptor proteins, small molecules, anti-sense oligonucleotides and other molecules having binding specificity. SBAs
5 may bind to an active or inactive form of the NNT-1 polypeptide, to any portion of the NNT-1 polypeptide and/or to the NNT-1 receptor. Suitable SBAs may be prepared using methods known in the art.

An exemplary NNT-1 polypeptide selective
10 binding agent of the present invention is an antibody, peptide, fusion peptide or soluble NNT-1 receptor protein that is capable of binding a certain portion of the NNT-1 polypeptide (as broadly defined above) and partially or completely inhibiting the binding of NNT-1
15 to its receptor. Similarly contemplated are selective binding agents, such as an antibody, peptide, fusion peptide, inactive form of NNT-1 or a small molecule that binds or otherwise prevents signal transduction at the site of the NNT-1 receptor.

20 As used herein, the terms "specific" and "specificity" refer to the ability of the selective binding agents to bind to NNT-1 polypeptides and not to bind to non-NNT-1 polypeptides. It will be appreciated, however, that the selective binding agents
25 may also bind orthologs of the polypeptide as set forth in SEQ ID NO: 2, that is, interspecies versions thereof, such as mouse and rat polypeptides.

A. ANTIBODIES AND DERIVATIVES THEREOF

30 A preferred embodiment of the present invention involves the use of selective binding agents such as antibodies and antibody fragments, derivatives and/or variations thereof that bind to either the NNT-1 polypeptide itself or its receptor. The antibodies may
35 be polyclonal including monospecific polyclonal, monoclonal (MAbs), recombinant, chimeric, humanized,

complementarity determining regions ("CDR")-grafted, human, single chain, and/or bispecific, hetero-antibodies, as well as fragments, variants or derivatives thereof that are capable of binding NNT-1 and partially or completely neutralizing NNT-1 activity or binding to the NNT-1 receptor, thereby blocking signal transduction.

Antibody fragments include those portions of the antibody which bind to an epitope on the NNT-1 polypeptide, an Fv, Fab, Fab' or F(ab)' fragment, or other fragments, variants, or derivatives thereof. Examples of such fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions.

Polyclonal antibodies directed toward an NNT-1 polypeptide generally are produced in animals (e.g., rabbits or mice) by means of multiple subcutaneous or intraperitoneal injections of an NNT-1 polypeptide and a suitable adjuvant. It may be useful to conjugate an NNT-1 polypeptide to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet hemocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals are bled and the serum is assayed for anti-NNT-1 polypeptide antibody titer.

Monoclonal antibodies directed toward an NNT-1 polypeptide are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the

hybridoma methods of Kohler et al., *Nature*, 256:495-497 (1975) and the human B-cell hybridoma method, Kozbor, *J. Immunol.*, 133:3001 (1984); Brodeur et al., *Monoclonal Antibody Production Techniques and Applications*, pp. 51-63 (Marcel Dekker, Inc., New York, 1987). Also contemplated are hybridoma cell lines which produce monoclonal antibodies reactive with NNT-1 polypeptides.

Monoclonal antibodies of the invention may be modified for use as therapeutics. One embodiment is a "chimeric" antibody in which a portion of the heavy and/or light chain is identical with or homologous to a corresponding sequence in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to a corresponding sequence in antibodies derived from another species or belonging to another antibody class or subclass. Also included are fragments of such antibodies, so long as they exhibit the desired biological activity. See, U.S. Patent No. 4,816,567; Morrison et al., *Proc. Natl. Acad. Sci.*, 81:6851-6855 (1985).

Also contemplated is the use of a "humanized" antibody, i.e., prepared so as to prevent or minimize an immune reaction to the antibody when administered to a patient. Methods for humanizing non-human antibodies are well known in the art. See U.S. Patent Nos. 5,585,089, and 5,693,762. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. Humanization can be performed, for example, using methods described in the art (Jones et al., *Nature* 321:522-525 (1986); Riechmann et al., *Nature*, 332:323-327 (1988); Verhoeyen et al., *Science* 239:1534-1536 (1988)), by substituting

Also encompassed by the invention is the use of human antibodies which bind NNT-1 polypeptides.

35 Human antibodies may also be produced by the
expression of recombinant DNA in host cells or by

35 Human antibodies may also be produced by the
expression of recombinant DNA in host cells or by

expression in hybridomas. Such hybridomas are generated by presenting the NNT-1 or a fragment thereof as an antigen to a selected mammal, followed by fusing cells (e.g., spleen cells) of the mammal with certain cancer cells to create immortalized cell lines by known techniques. The methods employed to generate such cell lines and antibodies directed against all or portions of a human NNT-1 polypeptide are further disclosed in Chang (U.S. Patent No. 5,741,772).

10 In an alternative embodiment, human antibodies can be produced from phage-display libraries (Hoogenboom *et al.*, *J. Mol. Biol.* 227:381 (1991); Marks *et al.*, *J. Mol. Biol.* 222:581 (1991). These processes mimic immune selection through the display of antibody repertoires on the surface of filamentous bacteriophage, and subsequent selection of phage by their binding to an antigen of choice. One such technique is described in PCT Application no. PCT/US98/17364, which describes the isolation of high affinity and functional agonistic antibodies for MPL- and msk- receptors using such an approach.

15 Chimeric, CDR-grafted, and humanized antibodies are typically produced by recombinant methods. Nucleic acids encoding the antibodies are introduced into host cells and expressed using materials and procedures described herein. In one embodiment, the antibodies are produced in mammalian host cells, such as CHO cells. Monoclonal (e.g., human) antibodies may be produced by the expression of recombinant DNA in host cells or by expression in hybridoma cells as described herein.

25 The anti-NNT-1 antibodies of the invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, Monoclonal Antibodies: A Manual of Techniques, pp.

5 The selective binding agents, including anti-NNT-1 antibodies, also are useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be administered to an animal, preferably into the bloodstream, and the presence and location of the
10 labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

35

B. PEPTIDES AND DERIVATIVES THEREOF

Also contemplated by the present invention is the use of peptides, modified peptides and fusion peptides which are capable of specifically binding to
5 NNT-1 polypeptides, fragments, derivatives, variants thereof and/or the NNT-1 receptor.

Specifically contemplated are peptides which may be fused to a homologous polypeptide to form a homodimer or to a heterologous polypeptide to form a
10 heterodimer. Heterologous peptide and polypeptides include, but are not limited to, a polypeptide or peptide which increases stability, such as an immunoglobulin constant region ("the Fc domain") and linkages to polymers such as polyethylene glycol
15 ("PEG") and dextran. When constructed together with a therapeutic protein, an Fc domain can, for example, provide a longer half-life or incorporate such functions as Fc receptor binding. Such modifications are discussed in detail in a patent application
20 entitled, "Modified Peptides as Therapeutic Agents," U.S. Ser. No. 09/428,082, PCT appl. no. WO.99/25044, which is hereby incorporated by reference in its entirety.

25 IV. THERAPEUTIC COMPOSITIONS AND ADMINISTRATION THEREOF

As used herein, the terms "effective amount" and "therapeutically effective amount" refer to the amount of an NNT-1 inhibitor necessary to support one
30 or more biological activities of: 1) inhibiting or reducing the expression, activity or production of the NNT-1; 2) inhibiting or reducing the ability of the NNT-1 polypeptide to bind to its receptor; 3) antagonizing the NNT-1 polypeptide and/or its receptor;
35 4) decreasing in vivo levels of NNT-1; and/or 5) decreasing serum level of IgE.

Methods of treating various IgE-related diseases or disorders using therapeutic compositions containing NNT-1 inhibitors are within the scope of the present invention. Such compositions may comprise a therapeutically effective amount of an NNT-1 inhibitor in admixture with a pharmaceutically acceptable carrier. The carrier material may be water for injection, preferably supplemented with other materials common in solutions for administration to mammals. Typically, an NNT-1 inhibitor therapeutic compound will be administered in the form of a composition comprising a purified NNT-1 inhibitor in conjunction with one or more physiologically acceptable carriers, excipients, or diluents. Neutral buffered saline or saline mixed with serum albumin are exemplary appropriate carriers. Preferably, the product is formulated as a lyophilizate using appropriate excipients (e.g., sucrose). Other standard carriers, diluents, and excipients may be included as desired. An exemplary composition comprises citrate buffer of about pH 4.0-4.5, which may further include NaCl.

The NNT-1 inhibitor compositions can be systemically administered parenterally. Alternatively, the compositions may be administered intravenously or subcutaneously. When systemically administered, the therapeutic compositions for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such pharmaceutically acceptable protein solutions, with due regard to pH, isotonicity, stability and the like, is within the skill of the art.

Therapeutic formulations of NNT-1 inhibitor compositions useful for practicing the present invention may be prepared for storage by mixing the selected composition having the desired degree of purity with optional physiologically acceptable

carriers, excipients, or stabilizers (*Remington's Pharmaceutical Sciences*, 18th edition, A.R. Gennaro, ed., Mack Publishing Company [1990]) in the form of a lyophilized cake or an aqueous solution. Acceptable

5 carriers, excipients or stabilizers are nontoxic to recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants such as ascorbic acid; low molecular

10 weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates

15 including glucose, mannose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, Pluronic or PEG.

20 The NNT-1 inhibitor composition to be used for *in vivo* administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes. Where the NNT-1 inhibitor composition is lyophilized, sterilization using these

25 methods may be conducted either prior to, or following, lyophilization and reconstitution. The composition for parenteral administration ordinarily will be stored in lyophilized form or in solution.

30 Therapeutic compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

 The route of administration of the composition is in accord with known methods, e.g. oral,

35 injection or infusion by intravenous, intraperitoneal, intracerebral (intraparenchymal),

intracerebroventricular, intramuscular, intraocular, intra-arterial, or intralesional routes, or by sustained release systems or implantation device which may optionally involve the use of a catheter. Where
5 desired, the compositions may be administered continuously by infusion, bolus injection or by implantation device. Alternatively or additionally, the NNT-1 inhibitor composition may be administered locally via implantation into the affected area of a
10 membrane, sponge, or other appropriate material on to which the composition has been adsorbed.

Where an implantation device is used, the device may be implanted into any suitable tissue or organ, such as, for example, into a cerebral ventricle
15 or into brain parenchyma, and delivery of an NNT-1 inhibitor composition may be directly through the device via bolus or continuous administration, or via a catheter using continuous infusion.

NNT-1 inhibitor compositions may be
20 administered in a sustained release formulation or preparation. Suitable examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, e.g. films, or microcapsules. Sustained release matrices include
25 polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamine (Sidman et al, *Biopolymers*, 22: 547-556 [1983]), poly (2-hydroxyethyl-methacrylate) (Langer et al., *J. Biomed. Mater. Res.*, 15: 167-277 [1981] and
30 Langer, *Chem. Tech.*, 12: 98-105 [1982]), ethylene vinyl acetate (Langer et al., *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also may include liposomes, which can be prepared by any of several methods known in the art
35 (e.g., DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA*, 82: 3688-3692 [1985]; Hwang et al., *Proc.*

Natl. Acad. Sci. USA, 77: 4030-4034 [1980]; EP 52,322; EP 36,676; EP 88,046; EP 143,949).

In some cases, it may be desirable to use NNT-1 inhibitor compositions in an *ex vivo* manner, i.e., to treat cells or tissues that have been removed from the patient and are then subsequently implanted back into the patient.

In other cases, NNT-1 inhibitor compositions may be delivered through implanting into patients certain cells that have been genetically engineered to express and secrete an NNT-1 inhibitor. Such cells may be animal or human cells, and may be derived from the patient's own tissue or from another source, either human or non-human. Optionally, the cells may be immortalized. The cells may be implanted into the brain, adrenal gland or into other suitable body tissues or organs of the patient.

In certain situations, it may be desirable to use gene therapy methods for administration of NNT-1 inhibitors to patients suffering from certain immunological disorders. In these situations, anti-sense strands of genomic DNA, cDNA, and/or synthetic DNA encoding the NNT-1 inhibitor or a fragment or variant thereof may be operably linked to a constitutive or inducible promoter that is active in the tissue into which the composition will be injected. This anti-sense NNT-1 inhibitor oligonucleotide, either inserted into a vector, or alone without a vector, can be injected directly. Alternatively, an anti-sense NNT-1 inhibitor DNA construct may be directly injected into muscle tissue where it can be taken up into the cells and expressed in the cells, provided that the anti-sense NNT-1 inhibitor DNA is operably linked to a promoter that is active in muscle tissue such as cytomegalovirus (CMV) promoter, Rous sarcoma virus (RSV) promoter, or muscle creatine kinase promoter.

Typically, the DNA construct may include (in addition to the anti-sense NNT-1 inhibitor DNA and a promoter), vector sequence obtained from vectors such as
5 retroviral vector, and/or a herpes virus vector. The vector/DNA construct may be admixed with a pharmaceutically acceptable carrier(s) for injection.

An effective amount of the NNT-1 inhibitor composition(s) to be employed therapeutically will
10 depend, for example, upon the therapeutic objectives such as the indication for which the NNT-1 inhibitor is being used, the route of administration, and the condition of the patient. Accordingly, it will be necessary for the therapist to titer the dosage and
15 modify the route of administration as required to obtain the optimal therapeutic effect. Typically, a clinician will administer the NNT-1 inhibitor composition until a dosage is reached that achieves the desired effect. The NNT-1 inhibitor composition may
20 therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of NNT-1 inhibitor) over time, or as a continuous infusion via implantation device or catheter.

25 As further studies are conducted, information will emerge regarding appropriate dosage levels for treatment of various conditions in various patients, and the ordinary skilled worker, considering the therapeutic context, the type of disorder under
30 treatment, the age and general health of the recipient, will be able to ascertain proper dosing.

V. CONDITIONS TO BE TREATED WITH NNT-1 INHIBITOR COMPOSITIONS

35 Since NNT-1 is expressed in immune system cells and in hematopoietic cells, NNT-1 inhibitors may

be useful to treat diseases caused by immune disorders and/or diseases caused by disorders of the hematopoietic system. Specifically, NNT-1 inhibitors may be used to treat patients who suffer from IgE-related immune diseases and disorders. There are several primary IgE-related immune disorders that are potential targets for NNT-1 inhibitors. Examples of such diseases include, but are not limited to, Type I allergic diseases, allergic rhinitis, eczema, dermatitis, pollinosis, dermatitis, anaphylactic shock, and asthma. Other diseases or disorders influenced by the dysfunction of allergic responses are encompassed within the scope of the invention.

The finding that NNT-1 stimulates antigen-specific IgE production importantly suggests that NNT-1 is specifically involved in the pathogenesis of allergy. By inhibiting or significantly decreasing the activity, expression or production of NNT-1 using NNT-1 inhibitors, the level of serum IgE may be reduced. A reduction in serum IgE levels has been shown to reduce symptoms of IgE related disease.

A non-exclusive list of additional acute and chronic IgE-related diseases which may be treated, diagnosed, ameliorated, or prevented by using NNT-1 inhibitors include:

- Diseases involving abnormal cell proliferation, including, but not limited to, cancer, arteriosclerosis and vascular restenosis. Other diseases influenced by the inappropriate proliferation of cells are also encompassed within the scope of the invention.
- Diseases and conditions relating to dysfunction of the immune system, including, but not limited to, rheumatoid arthritis, psoriatic arthritis,

inflammatory arthritis, osteoarthritis,
inflammatory joint disease, autoimmune disease,
multiple sclerosis, lupus, diabetes, inflammatory
bowel disease, transplant rejection, and graft vs.
5 host disease. Other diseases influenced by the
dysfunction of the immune system are encompassed
within the scope of the invention.

- Reproductive diseases and disorders, including,
but not limited to, infertility, miscarriage,
10 preterm labor and delivery, and endometriosis.
Other diseases of the reproductive system are
encompassed within the scope of the invention.
- Other diseases caused by or related by undesirable
levels of IgE are encompassed within the scope of
15 the invention.

VI. DIAGNOSTIC AND OTHER RELATED USES OF NNT-1 INHIBITORS

In addition to use as therapeutics, the NNT-1
20 inhibitor compositions disclosed herein may have
additional IgE-related uses. For example, these
compositions may further be used for *in vivo* and *in*
vitro diagnostic purposes, such as in labeled form to
detect the presence of NNT-1 and/or IgE in a body
25 fluid.

NNT-1 inhibitors, particularly antibodies,
may also be employed in any known assay method, such as
competitive binding assays, direct and indirect
sandwich assays, and immunoprecipitation assays (Sola,
30 Monoclonal Antibodies: A Manual of Techniques, pp.
147-158 (CRC Press, Inc., 1987)) for the detection and
quantitation of NNT-1 polypeptides as an indicator of
serum IgE levels. The antibodies will bind NNT-1
polypeptides with an affinity which is appropriate for
35 the assay method being employed.

For diagnostic applications, in certain embodiments, NNT-1 inhibitors may be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or an enzyme, such as alkaline phosphatase, β -galactosidase, or horseradish peroxidase (Bayer et al., *Meth. Enz.*, 184:138-163 (1990)).

Competitive binding assays rely on the ability of a labeled standard (e.g., an NNT-1 polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (an NNT-1 polypeptide) for binding with a limited amount of anti NNT-1 antibody. The amount of an NNT-1 polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three part complex. See, e.g., U.S. Patent No. 4,376,110. The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-

immunoglobulin antibody that is labeled with a detectable moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the
5 detectable moiety is an enzyme.

The assays described below provide examples of methods useful for identifying compounds that could inhibit NNT-1 activity. For ease of reading, the following definition is used herein for describing the
10 assays: "Test molecule(s)" refers to the molecule(s) that is under evaluation as an inhibitor of NNT-1, typically by virtue of its potential ability to block the interaction of NNT-1 with its receptor.

The NNT-1 receptor may be isolated, for
15 example, by expression cloning using labeled (e.g., iodinated) NNT-1.

Several types of *in vitro* assays using purified protein may be conducted to identify those compounds that disrupt NNT-1 activity. Such disruption
20 may be accomplished by a compound that typically inhibits the interaction of NNT-1 with its receptor.

In one assay, purified NNT-1 protein or a fragment thereof (prepared for example using methods described above) can be immobilized by attachment to
25 the bottom of the wells of a microtiter plate. Radiolabeled NNT-1 receptor, as well as the test molecule(s) can then be added either one at a time or simultaneously to the wells. After incubation, the wells can be washed and counted using a scintillation
30 counter for radioactivity to determine the degree of NNT-1/receptor binding in the presence of the test molecule. Typically, the molecule will be tested over a range of concentrations, and a series of control
35 "wells" lacking one or more elements of the test assays can be used for accuracy in evaluating the results. A variation of this assay involves attaching the receptor

to the wells, and adding radiolabeled NNT-1 along with the test molecule to the wells. After incubation and washing, the wells can be counted for radioactivity.

Several means including radiolabeling are available to "mark" NNT-1. For example, NNT-1 protein can be radiolabeled using 125-I or 35-S. Alternatively, a fusion protein of NNT-1 wherein the DNA encoding NNT-1 is fused to the coding sequence of a peptide such as the *c-myc* epitope. NNT-1-myc fusion protein can readily be detected with commercially available antibodies directed against *myc*.

An alternative to microtiter plate type of binding assays comprises immobilizing either NNT-1 or its receptor on agarose beads, acrylic beads or other types of such inert substrates. The inert substrate containing the NNT-1 or its receptor can be placed in a solution containing the test molecule along with the complementary component (either receptor or NNT-1 protein) which has been radiolabeled or fluorescently labeled; after incubation, the inert substrate can be precipitated by centrifugation, and the amount of binding between NNT-1 and receptor can be assessed using the methods described above. Alternatively, the insert substrate complex can be immobilized in a column and the test molecule and complementary component passed over the column. Formation of the NNT-1/receptor complex can then be assessed using any of the techniques set forth above, *i.e.*, radiolabeling, antibody binding, or the like.

Another type of *in vitro* assay that is useful for identifying a molecule to inhibit NNT-1 activity is the Biacore assay system (Pharmacia, Piscataway, NJ) using a surface plasmon resonance detector system and following the manufacturer's protocol. This assay essentially involves covalent binding of either NNT-1 or its receptor to a dextran-coated sensor chip which

is located in a detector. The test molecule and the complementary component can then be injected into the chamber containing the sensor chip either simultaneously or sequentially, and the amount of binding of NNT-1/receptor can be assessed based on the change in molecular mass which is physically associated with the dextran-coated side of the of the sensor chip; the change in molecular mass can be measured by the detector system.

In some cases, it may be desirable to evaluate two or more test molecules together for use in decreasing or inhibiting NNT-1 activity. In these cases, the assays set forth above can be readily modified by adding such additional test molecule(s) either simultaneously with, or subsequently to, the first test molecule. The remainder of steps in the assay can be as set forth above.

The NNT-1 inhibitors disclosed herein, including anti-NNT-1 antibodies, also are useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

VII. Use of Transgenic Mammals

Also included within the scope of the present invention are methods of modulating IgE levels using non-human mammals such as mice, rats, rabbits, goats, or sheep in which the gene (or genes) encoding the human equivalent of NNT-1 has been disrupted ("knocked out") such that the level of expression of this gene is significantly decreased or completely abolished. Such

mammals may be prepared using techniques and methods such as those described in U.S. Patent No. 5,557,032. The methods of the present invention further include modulating IgE levels using non-human mammals such as mice, rats, rabbits, goats, or sheep in which the gene (or genes) encoding the NNT-1 (either the native form of NNT-1 for the mammal or a heterologous NNT-1 gene) is over expressed by the mammal, thereby creating a "transgenic" mammal. Such transgenic mammals may be prepared using well known methods such as those described in U.S. Patent No 5,489,743 and PCT patent application no. WO94/28122, published 8 December 1994.

These non-human animals may be used for drug candidate screening. In such screening, the impact of a drug candidate on the animal may be measured. For example, drug candidates may decrease or increase the expression of the NNT-1 gene. In certain embodiments, the amount of NNT polypeptide that is produced may be measured after the exposure of the animal to the drug candidate. Additionally, in certain embodiments, one may detect the actual impact of the drug candidate on the animal. For example, the overexpression of a particular gene may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to prevent or inhibit a pathological condition. In other examples, the overproduction of a particular metabolic product such as a fragment of a polypeptide may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product or its ability to prevent or inhibit a pathological condition.

The following examples are intended for illustration purposes only, and should not be construed as limiting the scope of the invention in any way.

EXAMPLE II

NNT-1 transgenic (Tg+) mice and control littermates (Tg-) were immunized as above (5 mg/Kg) and bled before immunization and 7 and 14 days after. NNT-1 Tg+ mice overexpress NNT-1 encoding sequence engineered in a gene containing the liver-specific apoE promoter. To induce total IgE, mice (Balb/c as above) received one daily i.p. injection of 5 mg/Kg of NNT-1 for 7 consecutive days. Control mice received NNT-1 solvent alone. Mice were then bled the day following the day of last injection.

NNT-1 Tg+ mice showed higher levels of anti-KLH IgE antibodies than control littermates 14 days after KLH immunization (Figure 6). Anti-KLH IgE antibodies were not detectable in any of the Tg+ or Tg- mice before KLH immunization and were detectable in only a few of them 7 days after KLH immunization. In an experiment of total IgE induction, NNT-1-treated mice showed a 22% increase of serum total IgE compared to control mice.

EXAMPLE III

Detection of anti-KLH IgE and of total IgE.

Anti-KLH IgE antibodies were measured in serum by ELISA. Briefly, plates were coated with KLH in PBS, blocked, and added with dilutions of standard and test samples. Captured anti-KLH IgE were revealed using an anti-mouse IgE biotinylated antibody and neutravidin-conjugated horse radish peroxidase. Total IgE were also measured in serum by ELISA. In this assay, plates were coated with an anti-mouse IgE antibody in PBS, blocked, and added with dilutions of standard and test samples. Captured IgE were revealed as above. Results were expressed in ug/ml and analyzed with the Student t test.

While the present invention has been described in terms of preferred embodiments, it was understood that variations and modifications will occur
5 to those skilled in the art. Therefore, it was intended that the appended claims cover all such equivalent variations which would come within the scope of the invention as claimed.

109430 704260